Page 13 - Aadi Bioscience News Today

Wall Street analysts expect Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) to report $510,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for Aadi Bioscience’s earnings, with the lowest sales estimate coming in at $250,000.00 and the highest estimate coming in at $780,000.00. The business is expected to announce […]

Aadi Bioscience (NASDAQ:AADI – Get Rating) had its price target cut by equities research analysts at HC Wainwright from $49.00 to $48.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 174.76% from the company’s previous […]

- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 ...

- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 ...

Insider analyzed hundreds of life-science companies to identify the 17 drug developers that are growing the fastest.

Equities research analysts expect Aadi Bioscience Inc (NASDAQ:AADI – Get Rating) to report $390,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aadi Bioscience’s earnings. The lowest sales estimate is $250,000.00 and the highest is $540,000.00. The firm is expected to issue its next earnings results […]

Aadi Bioscience (NASDAQ:AADI – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.82) by $0.05, MarketWatch Earnings reports. Shares of NASDAQ:AADI traded down $0.54 during trading on Friday, reaching $18.95. The stock had a trading volume […]

Fyarro is now available for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Fyarro is now available for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.

Although the COVID-19 pandemic that defined 2020 continued to shape much of the life sciences industry in 2021, the way that it did was markedly different.